Hester Biosciences
- Market cap
- ₹ 1,730 Cr.
- P/E
- 35.6x
- P/B
- 5.07x
- 52-week range
- 1,239.3 – 2,683.6
- ROE
- 16%
- ROCE
- 15%
- Dividend yield
- 0.5%
- Debt / equity
- 0.54
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Hester Biosciences Limited is an India-based animal healthcare company. The Company is principally engaged in manufacturing poultry vaccines, large animal vaccines, and trading poultry, large animal, and petcare health products. Its segments include Poultry Healthcare, Animal Healthcare, and Others. The Poultry Healthcare vaccines include Gumboro I, Inactivated Chick ND, Inactivated Coryza, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IBD, among others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, PPR Vaccine - Sungri/96, among others. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet, Pawfresh, Synoton, Petsglow, Vitacoat, WormPeril, Hestaliv, TumOnzym and Safeline Spot. Its manufacturing facility is located at Village Meda-Adraj, Taluka Kadi, Mehsana District, Gujarat.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Hester Biosciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)35.6 against a typical 34.6: pricier than most peers (1st = cheapest).117th of 220
- Sales growth−8.3% against a typical +15.6% from a year earlier.160th of 197
- Profit growth+470.6% against a typical +18.9% from a year earlier.9th of 160
- Share price, 3 months−10.6% against a typical −0.5%.147th of 200
- Size₹ 1,729.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).76th of 199
Latest announcements
Exchange filings and their impact on the company.
- Hester to invest Rs 1.05 cr for 26% in solar captive SPV to cut power costs.
Hester Biosciences board on 6 October 2026 approved investment of up to Rs 1.05 crore for a 26% stake in SLYCE Agri World LLP, a solar power SPV. The stake is required under captive power rules to buy electricity under a Power Purchase Agreement, with completion in six months. The tiny outlay should lower factory power costs and aid margins over the next year.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB+ by CARE- CARE lowered its rating on 23 Mar 2026.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BBB+ | Stable | 7 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 7 Sep 2026 | ▲ Upgrade1 notch | CARE BBB → CARE BBB+ | — | CARE | ₹ 113.67 Cr. | |
| 23 Mar 2026 | ▼ Downgrade | CARE BBB | — | CARE | ₹ 131.47 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 30 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 30 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 4 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 1 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 9 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70 | 67 | 79 | 82 | 84 | 63 | 82 | 84 | 71 | 77 | 100 | 77 |
| Expenses | 57 | 57 | 63 | 65 | 65 | 58 | 63 | 61 | 59 | 60 | 66 | 54 |
| Operating Profit | 13 | 10 | 16 | 18 | 19 | 5 | 19 | 23 | 12 | 18 | 34 | 23 |
| OPM % | 19% | 15% | 20% | 21% | 23% | 8% | 23% | 27% | 17% | 23% | 34% | 29% |
| Other Income | 6 | 2 | 5 | 2 | 3 | 9 | −6 | 3 | 12 | 2 | 2 | 89 |
| Interest | 8 | 2 | 7 | 5 | 6 | −4 | 6 | 2 | 2 | 2 | 5 | 3 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | 7 |
| Profit before tax | 7 | 6 | 10 | 11 | 12 | 13 | 4 | 20 | 17 | 14 | 25 | 102 |
| Tax % | 40% | 37% | 35% | 29% | 29% | 15% | 59% | 14% | 16% | 31% | 34% | 5% |
| Net Profit | 4 | 4 | 6 | 7 | 8 | 11 | 2 | 17 | 14 | 9 | 17 | 97 |
| EPS in Rs | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 | 16.99 | 10.31 | 18.78 | 114 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- 4%
- 10 Years
- 11%
- 5 Years
- 8%
- 3 Years
- 26%
- TTM
- 41%
- 10 Years
- 12%
- 5 Years
- 1%
- 3 Years
- 12%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 12%
- 3 Years
- 11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Hester Biosciences | ₹ 2,232.00 | ₹ 1,730 Cr. | 35.6x | 5.1x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
Management
- Rajiv Dinesh Gandhi
- Chief Executive Officer, Managing Director, Executive Director
- Ashish Dineshbhai Desai
- Chief Financial Officer
- Vinod Mali
- Compliance Officer, Company Secretary
- Priya Rajiv Gandhi
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.